Back

The use of warfarin as part of antithrombotic strategy after transcutaneous aortic valve replacement is not associated with better medium-term outcomes

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Challenges in cardiovascular pharmacotherapy in patients who are older or with comorbidities Anticoagulants ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Assistant Professor Jwan Naser

Mayo Clinic, Rochester (United States of America)

7 More presentations in this session

Presentation thumbnail
Direct oral anticoagulants compared to vitamin K antagonists for the treatment of left ventricular thrombi
Doctor H. Morgan (London, GB)
Abstract Slides
Presentation thumbnail
Frailty and outcomes in octogenarians with atrial fibrillation treated with edoxaban: ESCAPE study
Doctor G. Denas (Motta Di Livenza, IT)
Abstract Slides
Presentation thumbnail
Oral anticoagulant therapy and decline of kidney function in elderly patients with non-valve atrial fibrillation: real world evidence data
Doctor G. Severini (Catanzaro, IT)
Abstract Slides
Presentation thumbnail
Previous antithrombotic therapy does not have an impact on the in-hospital mortality of patients with upper gastrointestinal bleeding
Doctor M. Hozman (Prague, CZ)
Abstract Slides
Presentation thumbnail
The association of angiotensin-converting enzyme inhibitors and angiotensin 2 receptor blockers with renal protection in patients with SARS-CoV-2
Mr S. Tan (New York, US)
Abstract Slides

Access the full session

Session thumbnail
Challenges in cardiovascular pharmacotherapy in patients who are older or with comorbidities

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Presentation
State-of-the-art lecture on pharmacotherapy for acute coronary syndromes
thumbnail
Webinar
Antithrombotic treatment for dual pathway inhibition in cardiovascular disease patients
thumbnail
Congress Presentation
State-of-the-art lecture on adjunctive antiplatelet therapy for patients undergoing percutaneous coronary intervention

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources